Search

Search Constraints

You searched for: Author/Creator Inman, David

Search Results

2. Efficacy, patient-reported outcomes, and safety of the anti-granulocyte macrophage colony-stimulating factor antibody otilimab (GSK3196165) in patients with rheumatoid arthritis: a randomised, phase 2b, dose-ranging study. (November 2020)

5. MRI of the joint and evaluation of the granulocyte–macrophage colony-stimulating factor–CCL17 axis in patients with rheumatoid arthritis receiving otilimab: a phase 2a randomised mechanistic study. (November 2020)

7. OP0228 GSK3196165 AN INVESTIGATIONAL ANTI-GM-CSF MONOCLONAL ANTIBODY, IMPROVES PATIENT REPORTED OUTCOMES IN A PHASE IIB STUDY OF PATIENTS WITH RHEUMATOID ARTHRITIS (RA). (June 2019)

8. Target engagement and cellular fate of otelixizumab: a repeat dose escalation study of an anti‐CD3ε mAb in new‐onset type 1 diabetes mellitus patients. Issue 4 (5th February 2019)